

PATIENT INFORMATION

Patient Name: _____ DOB: _____ Phone: _____ Sex: M F Ht: _____ Wt: _____ lbs kg

Primary Language: _____ Allergies: _____

Patient Preferred Location: _____

<ICD 10 CODE REQUIRED> DIAGNOSIS & CLINICAL INFORMATION

ICD 10 Code

D58.8 Other Specified Hereditary Hemolytic Anemias
D59.3 Hemolytic Uremic Syndrome
D59.4 Other Non-Autoimmune Hemolytic Anemias (Including Microangiopathic Hemolytic Anemia)
D59.5 Paroxysmal Nocturnal Hemoglobinuria
D59.8 Other Acquired Hemolytic Anemias

ICD 10 Code

G36.0 Neuromyelitis Optica
G70.00 Generalized Myasthenia Gravis, w/o Acute Exacerbation
G70.01 Generalized Myasthenia Gravis, w/Acute Exacerbation
Other: _____

Prescribing Information

Meningococcal document required for all diagnoses. See Pre-Medications and Required Labs by diagnosis below.

REQUIRED: Demographics & Most Recent: H&P, clinical notes, & medication list. Supporting clinical notes to include any past tried and/or failed therapies, intolerance, outcomes, or contraindications to conventional therapy.
LAB RESULTS: Include labs to support diagnosis.

PRESCRIPTION

SOLIRIS (eculizumab)

Administer over at least 35 minutes in adults, not to exceed 2 hours.

PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)

Loading Dose

IV: Infuse 600 mg dose weekly for first 4 weeks followed by 900 mg dose at week 5

Maintenance Dose

IV: Infuse 900 mg dose every 2 weeks for one year

ATYPICAL HEMOLYTIC UREMIC SYNDROME (aHUS)

Loading Dose

IV: Infuse 900 mg dose weekly for first 4 weeks followed by 1200 mg dose at week 5

Maintenance Dose

IV: Infuse 1200 mg dose every 2 weeks for one year

GENERALIZED MYASTHENIA GRAVIS (gMG) and NEUROMYELITIS OPTICA SPECTRUM DISORDER (NMOSD)

Loading Dose

IV: Infuse 900 mg dose weekly for first 4 weeks followed by 1200 mg dose at week 5

Maintenance Dose

IV: Infuse 1200 mg dose every 2 weeks for one year

Pre-Medications

Acetaminophen: 650 mg PO
Cetirizine: 10 mg PO
Diphenhydramine: 25 mg PO
Diphenhydramine: 25 mg IVP
Other: _____

Pre-Medications

Acetaminophen: 650 mg PO
Cetirizine: 10 mg PO
Diphenhydramine: 25 mg PO
Diphenhydramine: 25 mg IVP
Other: _____

Pre-Medications

Acetaminophen: 650 mg PO
Cetirizine: 10 mg PO
Diphenhydramine: 25 mg PO
Diphenhydramine: 25 mg IVP
Other: _____

SOLIRIS	DILUENT VOLUME	FINAL VOLUME
300 mg	30 mL	60 mL
600 mg	60 mL	120 mL
900 mg	90 mL	180 mL
1200 mg	120 mL	240 mL

Required Labs

- Baseline Serum Lactate Dehydrogenase (LHD) Hemoglobin Level
- Documented Meningococcal Vaccine

Required Labs

- Baseline Serum Lactate Dehydrogenase (LHD) Hemoglobin Level
- Serum Creatinine/eGFR
- Platelet Count
- Plasma Exchange
- Documented Meningococcal Vaccine

Required Labs

- Positive Serologic Test for Anti-AChR Antibodies
- Documented Meningococcal Vaccine

Is the patient on any other disease modifying therapy? Yes No
If yes, please note therapy and last dose: _____

Post Treatment Observations: The patient is observed for 60 minutes following the first administration.

Adverse Events: In the event of an adverse reaction occurring at a Medix Infusion suite, utilize the Medix Infusion adverse reactions protocol.

PRESCRIBER INFORMATION

Prescriber Name: _____ Signature: _____

Date: _____ NPI #: _____ Specialty: _____

Supervising Physician: _____ (If Applicable)

Address: _____ City: _____ State: _____ Zip: _____

Contact Name: _____ Phone: _____ Fax: _____ Email: _____